10582856 - GAU: 1625 Receipt date: 05/21/2008

| | | | SUBSTITUTE for U. | PTO/SB/08A (11-07), "Information Disclosure Statement by Applicant" S, Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE | |
|-----------------------------|---------------------------|---|---|--|--|
| ubstitute for form 1449/PTO | | | COMPLETE IF KNOWN | | |
| NFORMATION | DIS | CLOSURE | Application Number | 10/582,856 | |
| STATEMENT BY APPLICANT | | | Filing Date | June 14, 2006 | |
| | | | First Named Inventor | Barrow, et al. | |
| , , , , | | | Group Art Unit | | |
| (use as many sneets | s as n | ecessary) | Examiner Name | | |
| 1 | of | 1 | Attorney Docket Number | 21592YP | |
| | NFORMATION TATEMENT BY | NFORMATION DIS TATEMENT BY AP (use as many sheets as n | NFORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheets as necessary) | bestidute for form 14409PTO NFORMATION DISCLOSURE TATEMENT BY APPLICANT (use as many sheets as necessary) Group Art Unit Examiner Name | |

| | | | | ENT DOCUMENTS | |
|-----------------------|-------------|------------------------------|----------------------------|--|---|
| Examiner Initials* | Cite No. | U.S. Patent Docume Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication o Cited Document MM-DD-YYYY |
| | | | (i) known) | | |
| | | PE | | | |
| | | 0111 | | | |
| | | MAY 2 1 2008 W | | | |
| | | STEW STEET | | | |
| | | THAU CHAPTE | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| - | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | - | | |
| | | | | | |
| - | | | | | |
| | | ı | 1 1 | | _ |

| | Cite No. | | Foreign Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|-----------------------|-------------|--------|-------------------------|----------------------------|---|--|
| Examiner Initials* | | Office | Number | Kind Code (if known) | | |
| | | 1 | WO 2004/024675 | | Pharmacia & UpJohn | 03/25/2004 |
| | | , | WO 2003/027068 | | Elan Pharmaceuticals, Inc. | 04/03/2003 |
| | | , | WO 2004/050619 | | Glaxo Group Limited | 06/17/2004 |
| | | , | WO 2004/080376 | | Glaxo Group Limited | 09/23/2004 |
| | | , | WO 2003/045903 | | SmithKline Beecham | 06/05/2003 |
| | | , | WO 2002/02512 | | Elan Pharmaceuticals, Inc. | 01/10/2002 |
| | | I | EP Communication in EPO | | | |
| | | | Appln No. 04 814 367.1 | | | 12/21/2007 |
| | | | | | | |
| | | | | | | |
| Examin | | /76 | nna Davis/ (08/19/2008) | | Date Considered | |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer semented form * IDS Form* (IDS Folder), Merck & Co., Inc., 12/1/2007 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/ (08/19/2008)